Effect of preexisting human leukocyte antigen donor-specific antibodies especially human leukocyte antigen-DQ on kidney transplant outcome
Frontiers in Nephrology · 12.03.2026 · 6
DOI: 10.3389/fneph.2026.1734903 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nephrology, online erschienen am 12.03.2026. Verfasst von Sonia Mehrotra und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology & Immunology, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh, India. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Anti-HLA-DQ donor-specific antibodies are increasingly recognized for their role in early rejection and compromised graft function following kidney transplantation.
Methods
A total of 119 prospective kidney transplant recipients were evaluated for pre-transplant HLA sensitization using single antigen bead (SAB) assays for class I and class II donor-specific antibodies (DSAs). All patients had negative complement-dependent cytotoxicity (CDC) crossmatch results; however, flow cytometry crossmatch was positive for T cells in three patients and showed borderline B-cell positivity in one patient. Of these patients, 100 proceeded to kidney transplantation, including 19 ABO-incompatible transplants. All recipients were followed for a minimum of 4 years post-transplant, and induction immunosuppression was administered using either anti-thymocyte globulin (ATG) or ATLG (Grafalon ® ).
Results
A total of 100 patients underwent kidney transplant. Among them, 34 recipients (34%) had class I HLA antibodies (MFI range: 9,057 to 757) and 5 had class I DSAs (MFI range: 2,084 to 822) without any rejection episodes. Thirty-eight patients (38%) tested positive for class II HLA antibodies, including 20 with anti-HLA-DQ (MFI range: 7,725 to 766); of these, eight had donor-specific anti-DQ antibodies. Only one patient, who underwent an ABO-incompatible transplant and had pre-transplant DQ DSA with MFI 7,725, developed biopsy-proven antibody-mediated rejection (ABMR) but recovered following treatment. All eight DQ DSA-positive recipients showed post-transplant MFI decline within 1 month. Rejection was notably infrequent in recipients who received Grafalon ® induction.
Conclusions
Preformed anti-HLA-DQ DSAs, especially with MFI >5,000 and in the context of ABO incompatibility, may predispose to AMR. DQ DSAs with lower MFI require vigilant monitoring due to the risk of post-transplant rebound. ATLG-based induction was associated with low rejection incidence and favorable short-term outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Molecular Biology & Immunology, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh, India.
- Department of Nephrology and Kidney Transplant Medicine, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh, India.
- Department of Kidney Transplant and Urology Institute, Medanta Super Speciality Hospital, Lucknow, Uttar Pradesh, India.
Zitieren
APA
Mehrotra, S., Sharma, R. K., Kapoor, R., Jaiswal, R. K., & Kapoor, R. (2026). Effect of preexisting human leukocyte antigen donor-specific antibodies especially human leukocyte antigen-DQ on kidney transplant outcome. Frontiers in Nephrology, 6. https://doi.org/10.3389/fneph.2026.1734903
Vancouver
Mehrotra S, Sharma RK, Kapoor R, Jaiswal RK, Kapoor R. Effect of preexisting human leukocyte antigen donor-specific antibodies especially human leukocyte antigen-DQ on kidney transplant outcome. Frontiers in Nephrology. 2026;6. doi:10.3389/fneph.2026.1734903
BibTeX
@article{Mehrotra2026,
author = {Mehrotra, Sonia and Sharma, Raj Kumar and Kapoor, Rakesh and Jaiswal, Rajesh Kumar and Kapoor, Rohit},
title = {Effect of preexisting human leukocyte antigen donor-specific antibodies especially human leukocyte antigen-DQ on kidney transplant outcome},
journal = {Frontiers in Nephrology},
year = {2026},
volume = {6},
doi = {10.3389/fneph.2026.1734903}
}
EUVIMED